Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
This article was originally published in The Tan Sheet
Executive Summary
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7. It is one of the first "NDA Deviations" to get the go-ahead from the agency; such an application is for a product that is comparable to products in a monograph but deviates in a significant way.
You may also be interested in...
OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
A menthol-containing topical antitussive drug with chewing gum as a delivery form necessitates submission of an NDA deviation, FDA states
OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
A menthol-containing topical antitussive drug with chewing gum as a delivery form necessitates submission of an NDA deviation, FDA states
OTC Antitussive Menthol Chewing Gum Requires NDA Deviation – FDA
A menthol-containing topical antitussive drug with chewing gum as a delivery form necessitates submission of an NDA deviation, FDA states